Nallamotu Sandhya, Reddy Mahith S
Department of Medicine, Kasturba Medical College, Manipal, Manipal, IND.
Cureus. 2024 Aug 26;16(8):e67849. doi: 10.7759/cureus.67849. eCollection 2024 Aug.
We present a rare case of an immunocompetent 49-year-old male agriculturalist from India diagnosed with pneumonia. species are ubiquitous gram-positive, partially acid-fast bacilli that predominantly infect immunocompromised individuals. Only 0.3% to 2.9% of all nocardiosis cases are attributed to . The patient presented with a 25-day history of wet cough and high-grade fever, with bilateral bronchial breath sounds on chest auscultation and findings consistent with pneumonia on chest X-ray. During hospitalization, multiple treatment revisions were made. On admission, empiric antibiotic therapy against community-acquired pneumonia was initiated. Later, GeneXpert sputum testing for complex (MTBC) was positive for MTBC DNA. Suspected tuberculosis with a secondary infection prompted a treatment switch to antitubercular therapy (ATT) along with meropenem. Despite changes to treatment, the patient continued to deteriorate with no signs of clinical improvement. ATT with meropenem was discontinued when a repeat GeneXpert for MTBC was negative, ruling out tuberculosis. Slow-growing bronchial wash culture identified the rare pathogen , prompting an urgent referral to a specialized Infectious Diseases team. Treatment was then tailored according to antibiotic resistance-sensitivity testing. Targeted multidrug antibiotic therapy with trimethoprim-sulfamethoxazole and amikacin against facilitated gradual clinical improvement. This case underscores the importance of considering uncommon pathogens in differential diagnosis and highlights the critical role of microbiological diagnostics in guiding effective treatment. Drug resistance and changing bacterial pathogenicity trends must not be overlooked. The round-about antibiotic treatment changes in this case point to the necessity for faster diagnostic methods in identifying species. Further research into rapid diagnostic methods and up-to-date treatment guidelines are warranted to optimize outcomes in nocardiosis management.
我们报告了一例罕见病例,一名来自印度的49岁免疫功能正常的男性农民被诊断为肺炎。诺卡菌属是普遍存在的革兰氏阳性、部分抗酸杆菌,主要感染免疫功能低下的个体。在所有诺卡菌病病例中,只有0.3%至2.9%归因于诺卡菌属。患者有25天的湿咳和高热病史,胸部听诊有双侧支气管呼吸音,胸部X线检查结果与肺炎相符。住院期间,进行了多次治疗调整。入院时,开始针对社区获得性肺炎进行经验性抗生素治疗。后来,针对结核分枝杆菌复合群(MTBC)的GeneXpert痰检测MTBC DNA呈阳性。疑似肺结核合并继发感染促使治疗改为抗结核治疗(ATT)并联合美罗培南。尽管治疗有所改变,但患者病情仍持续恶化,没有临床改善的迹象。当重复进行的MTBC GeneXpert检测为阴性,排除肺结核后,停用了美罗培南联合ATT。生长缓慢的支气管灌洗培养鉴定出这种罕见病原体诺卡菌属,促使紧急转诊至专业传染病团队。然后根据抗生素耐药性-敏感性检测调整治疗方案。使用甲氧苄啶-磺胺甲恶唑和阿米卡星针对诺卡菌属进行靶向多药抗生素治疗,使临床症状逐渐改善。该病例强调了在鉴别诊断中考虑罕见病原体的重要性,并突出了微生物诊断在指导有效治疗中的关键作用。耐药性和不断变化的细菌致病性趋势不容忽视。该病例中迂回的抗生素治疗变化表明,需要更快的诊断方法来鉴定诺卡菌属。有必要进一步研究快速诊断方法和最新治疗指南,以优化诺卡菌病管理的结果。